{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:58:19Z","timestamp":1772035099224,"version":"3.50.1"},"reference-count":81,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2020,3,3]]},"DOI":"10.1080\/13543784.2020.1727884","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T13:09:48Z","timestamp":1581080988000},"page":"245-257","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["The treatment of acute agitation associated with schizophrenia or bipolar disorder: investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy"],"prefix":"10.1080","volume":"29","author":[{"given":"Kristen","family":"Ward","sequence":"first","affiliation":[{"name":"Clinical Pharmacy Department, University of Michigan College of Pharmacy, Ann Arbor, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Citrome","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Science, New York Medical College, Valhalla, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,2,26]]},"reference":[{"key":"cit0001","first-page":"327","volume":"26","author":"Mohr P","year":"2005","journal-title":"Neuro Endocrinol Lett"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1490-0"},{"key":"cit0003","first-page":"92","volume":"29","author":"Correll CU","year":"2017","journal-title":"Ann Clin Psychiatry"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1097\/01.pra.0000398410.21374.7d"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.165.1.107"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-31523"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1111\/appy.12209"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2010.12.024"},{"key":"cit0009","volume":"10","author":"NICE","year":"2015","journal-title":"Br Psychol Soc"},{"key":"cit0010","first-page":"89","volume":"1","author":"Allen MH","year":"2001","journal-title":"Postgrad Med"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2015.1132007"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.5811\/westjem.2011.9.6864"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(01)00052-8"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"cit0015","first-page":"331","volume":"68","author":"Lindenmayer JP, Brown E","year":"2004","journal-title":"An Excitement Subscale Of The Positive and Negative Syndrome Scale. an Excitement Subscale Of The Positive and Negative Syndrome Scale. Schizophr Res."},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-9-18"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-6757(02)42249-8"},{"key":"cit0018","first-page":"241","volume":"28","author":"Yu X","year":"2016","journal-title":"Shanghai Arch Psychiatry"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S173567"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2019.01.014"},{"key":"cit0021","first-page":"214","volume":"13","author":"Griffin CE","year":"2013","journal-title":"Ochsner J"},{"key":"cit0022","unstructured":"West-Ward Pharmaceuticals Corp. ATIVAN- lorazepam injection. Product label. Revised 04\/2017. [cited 2019 Oct 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/018140s028lbl.pdf"},{"key":"cit0023","unstructured":"Valeant Pharmaceuticals International, Inc. Ativan C-IV (lorazepam) tablets. Product label. Revised 12\/2016. [cited 2019 Oct 15]. Available from: https:\/\/www.bauschhealth.com\/Portals\/25\/Pdf\/PI\/Ativan-PI.pdf"},{"key":"cit0024","unstructured":"Hospira Inc. MIDAZOLAM HYDROCHLORIDE- midazolam hydrochloride injection, solution. Product label. Revised 07\/2019. [cited 2019 Oct 13]. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=1abda8b8-48a8-4995-af86-39220d1aa240"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sby056"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-100766"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182900fd6"},{"key":"cit0028","first-page":"CD006391","volume":"11","author":"Dold M","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v6.i4.391"},{"key":"cit0030","first-page":"862","volume":"40","author":"Jones KA","year":"2011","journal-title":"Aust Fam Physician"},{"key":"cit0031","first-page":"800","volume":"39","author":"Donlon PT","year":"1978","journal-title":"J Clin Psychiatry"},{"key":"cit0032","first-page":"CD007445","author":"Ahmed U","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0033","first-page":"CD002830","volume":"12","author":"Khokhar MA","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0034","unstructured":"Janssen Pharmaceuticals. Inc. HALDOL brand of haloperidol injection (For immediate release). (Product label). Revised 03\/2019. [cited 2020 Jan 27]. Available from: http:\/\/www.janssenlabels.com\/packageinsert\/product-monograph\/prescribing-information\/HALDOL-pi.pdf"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2017.11.031"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.7b00018"},{"issue":"7","key":"cit0037","first-page":"CD009377","volume":"2017","author":"Ostinelli EG, Brooke-Powney MJ","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0038","unstructured":"Galen. ADASUVE (loxapine) inhalation powder, for oral inhalation use. Product label. Revised 02\/2017. [cited 2019 Oct 7]. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528"},{"key":"cit0039","unstructured":"Ferrer Internacional. ADASUVE (loxapine) inhalation powder. Product label. [cited 2020 Jan 20]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adasuve-epar-product-information_en.pdf"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2011.00975.x"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.10m06011yel"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.110.081513"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2018.03.010"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000325"},{"key":"cit0045","unstructured":"Otsuka Pharmaceutical Co. ABILIFY (aripiprazole) tablets, ABILIFY DISCMELT (aripiprazole) orally disintegrating tablets, ABILIFY (aripiprazole) oral solution, ABILIFY (aripiprazole) injection for intramuscular use only. Product label. Revised 08\/2019. [cited 2020 Jan 20]. Available from: www.fda.gov\/medwatch"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b13e318033bd5e"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0115"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0541-x"},{"key":"cit0049","author":"Ostinelli EG","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0050","unstructured":"Pfizer. GEODON-ziprasidone hydrochloride capsule, GEODON-ziprasidone mesylate injection, powder, lyophilized, for solution. Product label. Revised 11\/2018. [cited 2019 Oct 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020825s053,020919s040,s021483s013lbl.pdf"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0104"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1007\/s002130000658"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.03.003"},{"key":"cit0054","unstructured":"Allergan. Saphris (asenapine) sublingual tablets. Product label. Revised 02\/2017. [cited 2019 Oct 13]. Available from: https:\/\/www.allergan.com\/assets\/pdf\/saphris_pi"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12262"},{"key":"cit0056","unstructured":"Janssen Pharmaceuticals. RISPERDAL (risperidone) tablets, RISPERDAL (risperidone) oral solution, RISPERDAL M-TAB (risperidone)orally disintegrating tablets. (Product label). Revised 01\/2019. [cited 2019 Oct 13]. Available from: http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribinginformation\/RISPERDAL-pi.pdf"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0303"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0315"},{"key":"cit0059","first-page":"CD009412","volume":"4","author":"Ostinelli EG","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0060","unstructured":"Precedex (Dexmedetomidine) [package insert]. Lake Forest (IL): Hospira Inc. 2018. [cited 2019 Sept 26]. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=548a88c0-afda-427e-75ac-5af0cfa2224c&type=display"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0507-7"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1590\/S0034-70942012000100015"},{"key":"cit0063","first-page":"61","volume":"85","author":"Doze V","year":"1989","journal-title":"Acta Vet Scand Suppl"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-198907000-00014"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.4.5.619"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01944.x"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S207016"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aep376"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.11124\/JBISRIR-2016-003096"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1111\/aas.12717"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199809000-00005"},{"key":"cit0072","unstructured":"Shrewsbury S, Swardstrom M, Satterly K, et al. SNAP 101: Randomized, Crossover, Active\/Placebo-Controlled, Safety and Pharmacokinetic\/Pharmacodynamic Study of 3 Ascending Doses of POD\u00ae Olanzapine. Poster presentation P8-162. Presented at the American Psychiatric Association (APA) Annual Meeting, May 18\u201322, 2019, San Francisco, CA"},{"key":"cit0073","unstructured":"Eli Lilly and Company. ZYPREXA - olanzapine tablet, ZYPREXA ZYDIS - olanzapine tablet, orally disintegrating, ZYPREXA INTRAMUSCULAR - olanzapine injection, powder, for solution. Product label. Revised 10\/2019. [cited 2020 Jan 26]. Available from: https:\/\/pi.lilly.com\/us\/zyprexa-pi.pdf"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937030-00001"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.5.441"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.7.1149"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200108000-00006"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-20"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2017.10.011"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S209284"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2018.09.208"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2020.1727884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T05:22:52Z","timestamp":1620451372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2020.1727884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,26]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3,3]]}},"alternative-id":["10.1080\/13543784.2020.1727884"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2020.1727884","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}